Join
Live feed
·
PRReleasevia Quantisnow
Fortress Biotech Inc. logo
Mustang Bio Inc. logo

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

ByQuantisnow·Wall Street's wire, on your screen.
FBIO· Fortress Biotech Inc.MBIO· Mustang Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBIO (Fortress Biotech Inc.), MBIO (Mustang Bio Inc.) and more on Quantisnow.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Quantisnow